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Aims Diuretics and renin–angiotensin–aldosterone system inhibitors are central in the treatment of hypertension, but may
cause serum potassium abnormalities. We examined mortality in relation to serum potassium in hypertensive patients.
Methods
and results
From Danish National Registries, we identified 44 799 hypertensive patients, aged 30 years or older, who had a serum
potassium measurement within 90 days from diagnosis between 1995 and 2012. All-cause mortality was analysed ac-
cording to seven predefined potassium levels: ,3.5 (hypokalaemia), 3.5–3.7, 3.8–4.0, 4.1–4.4, 4.5–4.7, 4.8–5.0, and
.5.0 mmol/L (hyperkalaemia). Outcome was 90-day mortality, estimated with multivariable Cox proportional hazard
model, with the potassium interval of 4.1–4.4 mmol/L as reference. During 90-day follow-up, mortalities in the seven
strata were 4.5, 2.7, 1.8, 1.5, 1.7, 2.7, and 3.6%, respectively. Adjusted risk for death was statistically significant for
patients with hypokalaemia [hazard ratio (HR): 2.80, 95% confidence interval (95% CI): 2.17–3.62], and hyperkalaemia
(HR: 1.70, 95% CI: 1.36–2.13). Notably, normal potassium levels were also associated with increased mortality: K: 3.5–
3.7 mmol/L (HR: 1.70, 95% CI: 1.36–2.13), K: 3.8–4.0 mmol/L (HR: 1.21, 95% CI: 1.00–1.47), and K: 4.8–5.0 mmol/L
(HR: 1.48, 95% CI: 1.15–1.92). Thus, mortality in relation to the seven potassium ranges was U-shaped, with the lowest
mortality in the interval of 4.1–4.4 mmol/L.
Conclusion Potassium levels outside the interval of 4.1–4.7 mmol/L were associated with increased mortality risk in patients with
hypertension.
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Introduction
The overall prevalence of hypertension in Europe is about 30–45%
of the total population1 with a treatment range from 11 to 66%.2
Many antihypertensive agents including diuretics, b-blockers,
angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin
receptor blockers (ARBs) can cause potassium disturbances3,4
and influence survival.5 Whereas the mechanisms that influence pa-
tient survival due to potassium disturbances are well known, little is
known about the optimal range of serum potassium in disease and
the levels associated with increased risk.6,7 The normal potassium
interval is defined based on apparently healthy individuals. The cur-
rent guidelines provide normal lower potassium limit from 3.5 to
3.8 mmol/L, while the upper limit is between 5.0 and 5.5 mmol/L.4,8,9
Well-defined hyperkalaemia and hypokalaemia in patients with
hypertension is known to increase the risk of death.5 In patients
with acute heart failure, potassium levels within the normal range
are associated with increased risk of death, highlighting that the
optimal level of potassium may differ from current definitions of
the normal range.10 Despite the widespread use of diuretics and
other drugs that influence potassium levels in patients with hyper-
tension, a search for optimal values of serum potassium has not
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been performed.3,5,9 To address this issue, we used data from .40
000 individuals with hypertension to examine the relation between
serum potassium and all-cause mortality.
Methods
Databases
All residents in Denmark have a personal, unique, and permanent
civil registration number that enables individual linkage of administrative
registries. The Danish National Patient Registry consists of informa-
tion about all hospital admissions since 1978. At discharge, each hospi-
talization is registered with one primary and, if applicable, one or more
secondary diagnoses according to the International Classification of
Disease (ICD). Until 1994, the 8th revision (ICD-8) was in use and
from 1994 onwards the 10th revision (ICD-10). The National Register
for Medicinal Statistics includes all dispensed prescriptions from Danish
pharmacies since 1995 based on the Anatomical Therapeutic Chemical
System (ATC). As the healthcare system is state financed and partly re-
imburses drug costs, all Danish pharmacies are legally required to regis-
ter all dispensed drug prescriptions, providing a valid and accurate
register. Date of death, date of birth, and vital status were obtained
from the Danish Register of Causes of Death and the Central Personal
Registry. Blood test results were obtained from electronic registries of
laboratory data, and we had access to data covering 1.5 million
individuals.
Study population
Hypertension was primarily defined by the use of at least two concomi-
tant antihypertensive drugs in two concomitant quarters. Patients en-
tered the study in the second quarter. This definition has previously
been validated: positive predictive value 80% and specificity 94.7%.1,11
We performed two sensitivity analyses where we selected the popula-
tion based on ICD codes and where we excluded patients receiving loop
diuretics. The first serum potassium measurement within 90 days of
antihypertensive treatment was selected. To avoid extreme outliers, pa-
tients with potassium levels ,2.9 mmol/L and .5.8 mmol/L were ex-
cluded. Patients under the age of 30 years were excluded because it is
unlikely that this group would have essential hypertension. The patients
were censored on 31 December 2012 or after 90-day follow-up. Pa-
tients with serum potassium measurements up to 90 days after dual
single-pill antihypertensive drug treatment were included in the study.
The outcome of the study was 90-day mortality from the date of serum
potassium measurement.
Co-morbidities and drugs
The statistical analyses were performed on patients stratified in groups
by the following potassium levels: ,3.5, 3.5–3.7, 3.8–4.0, 4.1–4.4,
4.5–4.7, 4.8–5.0, and .5.0 mmol/L. Hypokalaemia was defined as
potassium ,3.5 mmol/L and hyperkalaemia as .5.0 mmol/L. Serum
potassium interval of 4.1–4.4 mmol/L was used as reference for statis-
tical analysis. The reference interval was chosen based on the restricted
cubic splines results, and also other analysis, which confirmed that the
lowest mortality risk was found in this range.
Besides age and gender, the following conditions present before
the date of hypertension were assessed and used as covariates in the
analysis: chronic obstructive pulmonary disease (ICD-8: 491, 492;
ICD-10: J42–44), stroke (ICD-8: 433–438; ICD-10: I61, I62, I63, I64,
DG458, DG459), acute myocardial infarction (ICD-10: I21), atrial
fibrillation (ICD-10: I48), heart failure (ICD-10: I50), and diabetes.12,13
Diabetes was defined as more than two dispensed prescriptions of
glucose-lowering drugs (ATC code A10; insulin or oral hypoglycaemic
agents), because patients with diabetes were not necessarily admitted
to hospital with this specific diagnosis.10,14– 16 Serum creatinine was ob-
tained within a week of serum potassium measurement. Patients with
renal insufficiency and missing creatinine levels were excluded. Renal in-
sufficiency was defined by a serum creatinine level: (i) .105 mmol/L for
men ,70 years, (ii) .125 mmol/L for men .70 years, (iii) .90 mmol/L
for women ,70 years, and (iv) .105 mmol/L for women .70
years.17,18 A total of 1857 patients did not have a serum creatinine meas-
urement. Serum sodium measured same day as serum potassium was
also identified.
Patients who prior to the administration of two concomitant antihy-
pertensives were diagnosed with acute (ICD-10: DN17, DN19, DR34)
chronic kidney disease, including proteinuria (ICD-10: DN02–08,
DN11–12, DN14, DN18–19, DN26, DN158–160, DN162–164,
DN168, DN313, DQ612–613, DQ615, DQ619, DE102, DE112,
DI120, DM300, DM319, DM321B) or primary hyperaldosteronism
(ICD-10: DE260), were also excluded.
We included the five most prescribed antihypertensive single-pill
drug combinations in the multivariable analysis: ACEIs/ARBs and
thiazide diuretics; ACEIs/ARBs and b-blockers; ACEIs/ARBs and calcium
channel blockers; ACEIs/ARBs, thiazide diuretics, and potassium
supplements; and b-blockers, thiazide diuretics, and potassium supple-
ments. The remaining possible combinations were categorized as other
combinations of antihypertensive medication. The combination of
ACEIs/ARBs with thiazide diuretics and potassium supplements was
used as reference for statistical analysis. The following medications
(ATC codes) were identified: renin–angiotensin system inhibitors
C09; calcium channel blockers C08; b-blockers C07; diuretics C03; anti-
adrenergic drugs C02A, C02B, and C02C; and other antihypertensives
C02DA, C02DB, C02DD, C02DG, and C02L. Apart from medication
for hypertension, we have also included potassium supplements
(ATC: A12B) in the multivariable statistical analysis.
Statistical analysis
Kaplan–Meier cumulative mortality curves were plotted for the seven
preselected potassium intervals to illustrate trends in mortality. Cox
proportional hazard regression models were used to determine
the risk of death in hypertensive patients with different potassium inter-
vals, adjusted for all covariates. To validate this statistical model, the
three Cox proportional hazard model assumptions were assessed: pro-
portionality, linearity, and interaction. As linearity assumption had not
been fulfilled regarding the continuous variable age, we predefined
four age intervals: 30–50 years, 51–70 years, 71–80 years, and .80
years. Age interval of 50–70 years was used as reference.
The association of potassium with mortality was also assessed using
restricted cubic splines with knots at the 10th, 25th, 50th, 75th, and 90th
percentiles of potassium.
Relative risks are presented as hazard ratios (HR) with 95%
confidence intervals (95% CI). P-values of ,0.05 were considered sig-
nificant. Analyses were performed with SAS (version 9.4, SAS Institute,
Cary, NC, USA) and R statistical software (version 3.0.1, R development
core team).
Results
Demographics
In the period 1995–2012, we identified 44 799 hypertensive
patients that had a potassium measurement within 90 days from
diagnosis. The average age in the population was 67.1 (+12.6)
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years. The characteristics of the population, reported according to
the seven potassium levels, are presented in Table 1. No significant
difference in gender distribution was observed within the total
population. Women were overall more susceptible to hypokal-
aemia, whereas men more often had hyperkalaemia. The overall po-
tassium distribution was mean 4.20 mmol/L and median 4.2 mmol/L.
The 25th and 75th percentiles for potassium were 3.92 and
4.5 mmol/L, respectively. Mean serum sodium was 139.7 (+3.9).
Of the patients, 5486 were prescribed antidiabetic drugs and
1% were treated with insulin. The other co-morbid conditions
such as atrial fibrillation, heart failure, and acute myocardial
infarction were present in a rate of 10% each.
The major antihypertensive drug combinations were ACEIs/ARBs
combined with thiazides and potassium supplement 13.5%; ACEIs/
ARBs with b-blockers 12%; ACEIs/ARBs with thiazide diuretics
11.4%; b-blockers combined with thiazides and potassium supple-
ment 7.4%; and ACEIs/ARBs with calcium channel blockers 7%. In
total, 21 494 patients were prescribed potassium supplements.
Serum potassium level was measured 36.6 (+25.6) days, on aver-
age, after administration of minimum two concomitant antihyper-
tensive drugs. Supplementary material online, S1 illustrates that in
the first 45 days from dual antihypertensive therapy initiation,
most potassium measurements are effectuated (65.1%) and most
events (death) registered (72.9%). As there can be seen in Supple-
mentary material online, S2, 74.8% of the total population was admi-
nistered diuretics and 70% ACEIs/ARBs. There can also be observed
that the administration of diuretics in the low normal potassium
level was slightly higher than the administration of ACEIs/ARBs.
Likewise, ACEIs/ARBs prescription was marginally higher than
diuretic prescription in the upper potassium interval.
Survival analysis
Survival curves are illustrated in Figure 1. Of the patients, 866 (1.9%)
died during the 90-day follow-up. Mortality in the seven strata
was low: 4.5, 2.7, 1.8, 1.5, 1.7, 2.7, and 3.6%, respectively. The highest
90-day mortality rates were observed in 2005 and 2010 with 80
and 83 observations, respectively. Univariate HRs of each potassium
level are shown in Figure 2. The lowest mortality risk was observed
in the interval of 4.1–4.4 mmol/L, while hypo- and hyperkalaemia
were associated with increased mortality. Risk of all-cause mortality
was also increased in potassium intervals: 3.5–3.7 and 4.8–
5.0 mmol/L. Likewise, we observed a trend towards excess mortal-
ity in the intervals of 3.8–4.0 and 4.5–4.7 mmol/L.
The results of the multivariable analysis with potassium 4.1–
4.4 mmol/L as reference are shown in Figure 3. After adjusting the
model for age, sex, biologically relevant co-morbidities, and con-
comitant medication, the mortality remained significantly increased
for all potassium ranges outside the interval of 3.8–4.7 mmol/L.
Being a female or over the age of 70 years were overall associated
with increased mortality. Patients with co-morbid conditions such
as chronic obstructive pulmonary disease, atrial fibrillation, heart
failure, and stroke also had an increased risk of death. Considering
the different antihypertensive drug combinations, we observed a
trend that ACEIs/ARBs in combination with thiazide diuretics
were a safe treatment (HR: 0.65, 95% CI: 0.42–1.01, P ¼ 0.05).
However, the combination of b-blockers with thiazide diuretics
and potassium supplements was associated with an increased
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mortality risk (HR: 1.46, 95% CI: 1.03–2.08, P ¼ 0.03). Moreover,
other single-pill antihypertensive drug combinations than the top
five included in the adjusted model were significantly associated
with increased risk of death, with HR 1.85.
The U-shaped restricted cubic splines curve shown in Figure 4
indicated that the lower and the higher the serum potassium level,
the greater the mortality risk. Additionally, the splines curve indi-
cated differences in risk within the normal potassium ranges, where
potassium interval of 4.1–4.4 mmol/L was associated with the
lowest risk of death.
Other analyses
Three additional sensitivity analyses were applied to verify the initial
findings. The results of these analyses are illustrated in Table 2. First,
we selected our hypertensive population based on ICD codes from
the National Patient Registry, and we included in the analysis
the patients who received minimum two concomitant antihyper-
tensive drugs in the interval of 90 days before the diagnosis or
30 days after the diagnosis. Potassium interval of 3.8–4.0 mmol/L
was no longer significantly associated with increased risk, although
with a clear tendency towards our initial findings (HR: 1.14, 95% CI:
0.98–1.32, P ¼ 0.10).
Second, we excluded patients who were administered loop diure-
tics according to the Prescription Registry as loop diuretics could in-
dicate heart failure. This analysis also showed that potassium level of
3.8–4.0 mmol/L was not significantly associated with the increased
risk of death, although evidently with the same overall trends as in
our initial findings (HR: 1.24, 95% CI: 0.94–1.64, P ¼ 0.12).
Third, we excluded patients who, prior hypertension date,
were diagnosed with myocardial infarction or heart failure as
both could be treated with medication used for hypertension.
This analysis showed that potassium levels outside the interval
of 4.1–4.7 mmol/L were associated with increased mortality risk.
Discussion
This study analysed the short-time mortality risk in relation to
different potassium intervals in hypertensive patients administered
various classes of blood-pressure-lowering drugs. The major finding
was that even mild deviations within the normal potassium range
(3.5–5.0 mmol/L) were associated with increased mortality.
Although it was expected that hypo- and hyperkalaemia would be
associated with increased risk of death, it was unexpected that three
normal potassium levels (K: 3.5–3.7, 3.8–4.0, and 4.8–5.0 mmol/L)
were also associated with a significantly increased mortality in
hypertensive patients.
We considered the time frame of potassium measurement within
90 days from start of antihypertensive treatment optimal for analys-
ing the acute mortality risk in patients with hypertension for two
reasons. First, Mcdowell and Ferner19 showed in a review about
monitoring of hypertensive patients for adverse drugs reactions
that the peak follow-up time of potassium and creatinine was
3 months and 1 year after treatment initiation, respectively. Second,
Podrid7 illustrated in a review that potassium concentrations were
directly related to the dosage of the administered diuretic. Low po-
tassium can be observed from 4 to 40 weeks after treatment with
diuretics in patients with hypertension. Moreover, Supplementary
material online, S1 reveal that the majority of the population had
a potassium measurement in the first 45 days (65.1%) and that
most of the patients deceased (72.9%) in the same timeframe. How-
ever, methodologically, it would not have been appropriate to re-
duce the follow-up time as a considerable number of patients did
not have their potassium measured and we would have missed
Figure 1 Kaplan–Meier analysis of the survival probability
among the different potassium intervals. n ¼ 44 799.
Figure 2 All-cause mortality in hypertensive patients stratified by potassium intervals (90-day follow-up). n ¼ 44 799. Reference interval
represented by the interval K: 4.1–4.4 mmol/L.
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27.1% of the events. Furthermore, a longer follow-up time would
have been a great bias, as data showed a trend in less potassium
measurement and less events over time. In as such, within a window
period of 90 days from hypertension treatment, we intended to
register both the immediate and the slow onset potassium disarrays.
It is important to acknowledge that all patients have been treated
with two antihypertensive drugs for two concomitant quarters
(180 days) before the first potassium measurement.
As for the definition of hypertension, Olesen et al.11 have vali-
dated the model of identifying hypertensive patients according to
blood-pressure-lowering drug prescriptions. Nevertheless, we per-
formed a sensitivity analysis where we attempted to identify major
difference in identification of hypertensive population based on ICD
codes vs. pharmacological treatment. We did not observe any major
difference in the association of the defined potassium intervals and
mortality risk. Moreover, the combination of ACEIs/ARBs with loop
diuretics can indicate heart failure and not hypertension.1 For this
reason, we completed a second sensitivity analysis where patients
with loop diuretic prescription were excluded. This analysis did
not show any considerable difference in results when compared
with the initial analysis. Additionally, we performed a third analysis
where patients with history of myocardial infarction and heart fail-
ure were excluded. This was because combination of ACEIs with
b-blockers could indicate one of the above mentioned conditions
and not hypertension.20,21 This analysis did not show major differ-
ence when compared with the other two sensitivity analysis, or
main analysis. Overall, these analyses showed almost identical re-
sults to our primary analysis, with small variations in statistical signifi-
cance probably related to fewer individuals in each potassium
interval group. All these analyses indicated that serum potassium
.4.0 and ,4.7 mmol/L is optimal in hypertensive patients.
To our knowledge, few, if any, studies3,9 have investigated which
potassium interval is the safest in hypertensive patients; most studies
have analysed the effect of different classes of antihypertensive
drugs on potassium homeostasis, mortality, and cardiovascular
and non-cardiovascular events. Alderman et al. demonstrated that
patients are more prone to hypokalaemia if treated with chlorthali-
done compared with amlodipine or lisinopril, and that hypokalaemic
patients have a higher mortality risk than do those with normokalae-
mia.12 Moreover, Ikram mentioned in his article ‘a crossover study
design in hypertensive patients with coronary disease’ that mild de-
grees of hypokalaemia induced by thiazide diuretics increased the
tendency to arrhythmia when compared with normokalaemia on
a potassium-sparing diuretic.22 –24 These findings are in agreement
with our study. We observed increased all-cause mortality in
hypokalaemic patients, and that thiazides in combination with
ACEIs/ARBs seemed to be particularly safe for hypertensive patients
when compared with the reference (ACEIs/ARBs combined with
Figure 3 All-cause mortality in hypertensive patients stratified by potassium intervals (90-day follow-up). n ¼ 44 799. Model adjusted for cov-
ariates. Reference interval represented by the interval K: 4.1–4.4 mmol/L; and single-pill combination of angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers, thiazide diuretics, and potassium supplements. ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers.
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thiazide diuretics and potassium supplements). Alderman et al. also
demonstrated that ACEIs increase the risk of elevated potassium
and that this patient group had ‘a significantly increased risk of com-
bined cardiovascular disease compared with normokalaemics’. Simi-
larly, our study demonstrated that hyperkalaemic patients are
associated with increased mortality risk compared with normoka-
laemic patients, and that patients in this group are characterized
by a higher administration rate of ACEIs/ARBs than are hypokalaem-
ic and normokalaemic patients. Nevertheless, several studies and
guidelines recommend dual therapy of ACEIs/ARBs with calcium
channel blockers, diuretics, or b-blockers.1,25,26 This statement is
strongly supported by our study that showed that single-pill
combination of ACEIs/ARBs with b-blockers and thiazide diuretics
was associated with decreased mortality risk, in spite of insignificant
P-values.
The study by Macdonald and Struthers was the only study/review
we identified that contained exact recommendations for a potas-
sium interval in patients with hypertension.9 The authors indicated
that it is favourable for hypertensive patients to maintain potassium
between 3.5 and 5.0 mmol/L. This was based on studies that evalu-
ate the link between hypokalaemia and development of ventricular
arrhythmias and sudden cardiac death. However, most of the cited
studies did not directly examine the relationship between serum
potassium and mortality in hypertensive patients.
Overall, we were unable to identify any studies that provide direct
evidence to select optimum levels of serum potassium in disease
or health. Here, we demonstrate a significantly increased risk of
death among hypertensive patients with serum potassium ,4.1
or .4.7 mmol/L.
Study limitations
The limitations largely relate to the observational nature of the
study. However, the Danish National Health registries contain
uniquely detailed information, and we were able to extract reliable
data on co-morbid illnesses and concomitant medication, as well as
potassium measurements and date of death, overall strengthening
the reliability of our findings. All factors that were considered pos-
sible confounders were included in the Cox multivariable analysis.
Limitations of this study are represented by the lack of informa-
tion regarding the cause of death. In certain circumstances, it might
Figure 4 Restricted cubic splines showing the adjusted hazard
ratios for all-cause mortality as a function of potassium concentra-
tion. Knots at the 10th, 25th, 50th, 75th, and 90th percentiles of
potassium. Model adjusted for age, sex, chronic obstructive pul-
monary disease, stroke, acute myocardial infarction, atrial fibrilla-
tion, heart failure, diabetes mellitus, potassium supplement,
angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers in combination with thiazides, angiotensin-converting en-
zyme inhibitors/angiotensin receptor blockers in combination with
calcium channel blockers, angiotensin-converting enzyme inhibi-
tors/angiotensin receptor blockers in combination with b-blockers,
b-blockers in combination with thiazides and potassium supple-
ments, and other single-pill antihypertensive drug combinations.
n ¼ 44 799. This figure shows an approximation of the function
relating serum potassium to the hazard rate of death, and should
not be interpreted with respect to some reference.
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Table 2 Sensitivity analysis 1 (hypertensive patients found according to International Classification of Disease codes)
and sensitivity analysis 2 (patients with loop diuretic prescription excluded from main analysis) and sensitivity analysis 3
(Patients with acute myocardial infarction or heart failure diagnosis before hypertension diagnosis were excluded from
the main analysis)
Potassium
(mmol/L)
Hypertension definition based
on ICD codes (n 5 26 126)
Patients with loop diuretic prescription
were excluded (n 5 35 393)
Patients with an acute myocardial
infarction or heart failure diagnosis
before hypertension were excluded
(n 5 35 827)
HR Low 95% High 95% P HR Low 95% High 95% P HR Low 95% High 95% P
2.9–3.4 1.91 1.63 2.24 ,0.01 3.49 2.43 5.00 ,0.01 2.99 2.21 4.06 ,0.01
3.5–3.7 1.49 1.28 1.74 ,0.01 2.03 1.48 2.79 ,0.01 1.89 1.44 2.48 ,0.01
3.8–4.0 1.14 0.98 1.32 0.10 1.24 0.94 1.64 0.12 1.31 1.04 1.66 0.02
4.1–4.4 1 Reference 1 Reference 1 Reference
4.5–4.7 1.18 0.98 1.43 0.07 0.95 0.69 1.30 0.74 1.18 0.91 1.53 0.22
4.8–5.0 1.38 1.07 1.78 0.01 1.50 1.01 2.22 0.04 1.85 1.34 2.55 ,0.01
5.1–5.8 2.20 1.66 2.91 ,0.01 1.89 1.11 3.24 0.02 2.13 1.37 3.29 ,0.01
Model adjusted for covariates. Reference interval represented by the interval K: 4.1–4.4 mmol/L.
All-cause mortality in hypertensive patients stratified by potassium intervals (90-day follow-up).
ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.
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be difficult to determine the primary cause of death when a patient
can be attributed one or more codes in situations where autopsy is
missing.
As the Danish National Health registries do not contain reliable
diagnostic codes for differentiating whether hypertension was diag-
nosed in hospital vs. general practitioner, we used an alternative mo-
dality based on a validated algorithm for identifying patients with
hypertension. Despite the high predictive value and specificity of
this method, misclassification of some patients as hypertensive
could occur. With regard to the definition of diabetes, we could en-
counter similar problems as with hypertension. Patients with dia-
betes who were treated by their general practitioner and never
hospitalized do not have diabetes diagnostic codes available. There-
fore, we considered that more than two prescriptions of glucose-
lowering drugs may increase the predictive value in our cohort.
However, misclassification cannot be excluded.
Furthermore, our population may not extend to other popula-
tions, which can lead to difficulty in reproducing these results world-
wide. Despite the fact that we performed three sensitivity analyses
to adjust for major confounders, we cannot exclude a possible effect
of unmeasured confounders. Additionally, the characteristics of the
patients with hypertension, who had a serum potassium measure-
ment within 90 days from dual single-pill therapy, may be different
from the hypertensive patients who did not have a potassium meas-
urement in this time interval. Moreover, it is discussable whether the
use of the first serum potassium measurement within the 90 days of
antihypertensive treatment was optimal for the analysis of 90-day
mortality. However, we observed decrease in both potassium mea-
surements and death rate in time. Last but not least, we cannot
affirm whether mortality is increased due to the influence of
potassium influence on myocardial membrane potential or it is a
marker of other processes.
Conclusion
In conclusion, our results strongly indicate that serum potassium
levels ,4.1 or .4.7 mmol/L are associated with a significantly
increased mortality in hypertensive individuals.
Clinical implications
This study indicates that low- and high-normal potassium levels may
be associated with increased risk of death, which suggests that a nar-
rower normal interval might improve outcome in patients with
hypertension. Most drugs against hypertension influence in some
way potassium homeostasis. Therefore, monitoring soon after the
onset of medication would probably be relevant to achieve stable
potassium levels and improve survival. Future studies that focus
on frequency of potassium measurement, potassium fluctuations
over time, and effect of potassium regulation on mortality can surely
complement this study’s findings.
Supplementary material
Supplementary material is available at European Heart Journal online.
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